Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Consolidation and Maintenance in Previously Untreated Marginal Zone Lymphoma
ChiCTR2500110878Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in marginal zone B-cell lymphoma (MZL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete remission rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2500110878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110878.